Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Liver Cancer treatment details. Chemotherapy. Immunotherapy. Hannover Medical School, Hannover, Germany

Survival: 11.8 months
Toxicity Grade: 3
Treatments: Chemotherapy
Country: Germany
City/State/Province: Hannover
Hospital: Hannover Medical School
Journal: Link
Date: 5/2010

This study involved 40 patients with advanced hepatocellular carcinoma, 35 of these were male. The average age was 66.5 years.

Patients were given GV1001, which is a telomerase peptide cancer vaccine (immunotherapy) intended to cause the immune system to attack cancer cells that have active telomerase. Prior to receiving the vaccine, patients were given the chemotherapy agent cyclophosphamide, which was used to block the effect regulatory T cells may have to prevent the immune response needed for GV1001 to work. Patients were also given the immunotherapy agent GM-CSF, which is used to stimulate cells of the immune system.

The highest grade of toxicity reported was grade 3, which was from one case of renal failure. Other toxicities were of grades 1 and 2, mostly related to injection site reactions.

The estimated median overall survival for this study was 11.8 months.

This study was supported by Pharmexa A/S Biosciences, the makers of GV1001.

Correspondence: Dr. Tim Greten; email:

E-mail to a Friend Email Physician More Information